AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30320204 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning with the thyroid gland facing the cathode end of the X-ray tube
Number of subjects: 48
Study 30320204 — intervention group
Group type: COMPARATOR
Intervention: Positioning with the thyroid gland facing the anode end of the X-ray tube
Number of subjects: 48
Study 30320410 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillators (ICDs)
Number of subjects: 3892
Study 30320410 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for refusal of ICD implantation
Number of subjects: 3892
Study 30320410 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing implant decision
Number of subjects: 3892
Study 30320410 — intervention group
Group type: EXPERIMENTAL
Intervention: Country differences in refusal rates
Number of subjects: 3892
Study 30321257 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity defined by BMI ≥30 or BF% >25% in men and >35% in women.
Number of subjects: 322
Study 30321257 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity defined by BF% >25% in men and >35% in women.
Number of subjects: 322
Study 30321257 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 322
Study 30321257 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BF%
Number of subjects: 322
Study 30321257 — intervention group
Group type: COMPARATOR
Intervention: Cox proportional hazards models adjusted for various factors including age, sex, diabetes mellitus, cardiovascular disease, estimated glomerular filtration rate, urine protein:creatinine ratio, high-sensitivity C-reactive protein, and use of renin-angiotensin-aldosterone system inhibitors or statins.
Number of subjects: 322
Study 30321282 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful weight-loss maintainers (WLMs)
Number of subjects: 102
Study 30321282 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight controls (NCs)
Number of subjects: 102
Study 30321282 — intervention group
Group type: COMPARATOR
Intervention: Controls with overweight/obesity (OCs)
Number of subjects: 102
Study 30321312 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin microbiota analysis in patients with cellulitis
Number of subjects: 58
Study 30321314 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of both NNRTI/nucleoside reverse transcriptase inhibitor PDR
Number of subjects: 1557
Study 30321314 — intervention group
Group type: EXPERIMENTAL
Intervention: Only NNRTI PDR
Number of subjects: 1557
Study 30321314 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of PDR at 20% threshold
Number of subjects: 1557
Study 30321314 — intervention group
Group type: COMPARATOR
Intervention: No PDR
Number of subjects: 1557
Study 30322817 — intervention group
Group type: EXPERIMENTAL
Intervention: One-view digital breast tomosynthesis
Number of subjects: 14848
Study 30322817 — intervention group
Group type: COMPARATOR
Intervention: Two-view digital mammography
Number of subjects: 14848
Study 30322833 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 636
Study 30322833 — intervention group
Group type: COMPARATOR
Intervention: Gain-framed messages
Number of subjects: 636
Study 30322836 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with atrial fibrillation (AF)
Number of subjects: 1800
Study 30322839 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth interventions (3 increasingly complex interventions)
Number of subjects: 163
Study 30322839 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 163
Study 30322839 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth interventions (2 most complex interventions)
Number of subjects: 163
Study 30322839 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 163
Study 30323149 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation targeted at the fornix
Number of subjects: 5
Study 30323658 — intervention group
Group type: EXPERIMENTAL
Intervention: MARA-1 group (hypofractionated radiotherapy): 40 Gy in 16 fractions with a concomitant boost of 4 Gy to breast.
Number of subjects: 447
Study 30323658 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard fractionated radiotherapy): 50.4 Gy in 28 fractions plus a sequential electron boost of 10 Gy in 4 fractions.
Number of subjects: 447
Study 30323658 — intervention group
Group type: EXPERIMENTAL
Intervention: MARA-1 group (hypofractionated radiotherapy).
Number of subjects: 447
Study 30323658 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard fractionated radiotherapy).
Number of subjects: 447
Study 30323863 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual allergen immunotherapy (SLIT) with house dust mite (HDM) extract
Number of subjects: 0
Study 30323863 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (non-allergic)
Number of subjects: 0
Study 30323946 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily activity feedback via smartwatch over a 9-hour period
Number of subjects: 52
Study 30323946 — intervention group
Group type: COMPARATOR
Intervention: No activity feedback
Number of subjects: 52
Study 30323946 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartwatch adherence
Number of subjects: 52
Study 30323946 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention rate at 3 months post-discharge
Number of subjects: 52
Study 30323946 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of outcome measures (EQ-5D-5L, WHODAS, RMI)
Number of subjects: 52
Study 30324088 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA × BSA
Number of subjects: 0
Study 30324088 — intervention group
Group type: COMPARATOR
Intervention: PASI
Number of subjects: 0
Study 30324541 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT-A injection
Number of subjects: 468
Study 30324586 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg bid) with Tamoxifen (60 mg loading dose qd days 10-13, 20 mg qd days 14-26)
Number of subjects: 79
Study 30324586 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg bid) with Anastrozole (1 mg qd days 10-19)
Number of subjects: 79
Study 30324586 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg bid) with Letrozole (2.5 mg qd days 10-38)
Number of subjects: 79
Study 30324586 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib monotherapy (300 mg bid continuously)
Number of subjects: 79
Study 30324653 — intervention group
Group type: EXPERIMENTAL
Intervention: Confusion Assessment Method for the ICU
Number of subjects: 74
Study 30324653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Care Delirium Screening Checklist
Number of subjects: 74
Study 30325462 — intervention group
Group type: EXPERIMENTAL
Intervention: Segment 1 (early NREM sleep)
Number of subjects: 41
Study 30325462 — intervention group
Group type: EXPERIMENTAL
Intervention: Segment 8 (late NREM sleep)
Number of subjects: 41
Study 30325462 — intervention group
Group type: EXPERIMENTAL
Intervention: First half of the night
Number of subjects: 41
Study 30325462 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis including REM sleep
Number of subjects: 41
Study 30325463 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 ≥100 cells/μL
Number of subjects: 736
Study 30325463 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 50-99 cells/μL
Number of subjects: 736
Study 30325463 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 <50 cells/μL
Number of subjects: 736
Study 30325534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (160-mg loading dose, 80 mg every 2 weeks for the first 12 weeks, then 80 mg every 4 weeks until Week 52)
Number of subjects: 78
Study 30325534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab retreatment (IXE Q4W for 192 weeks)
Number of subjects: 78
Study 30325534 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Withdrawal Period (Weeks 52 to 100)
Number of subjects: 78
Study 30325534 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Withdrawal Period
Number of subjects: 78
Study 30325534 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment Period
Number of subjects: 78
Study 30325779 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected individuals with reduced subcutaneous adipose tissue (SAT)
Number of subjects: 225
Study 30325779 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected individuals with reduced SAT
Number of subjects: 225
Study 30325779 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected individuals with increased visceral adipose tissue (VAT)
Number of subjects: 225
Study 30325779 — intervention group
Group type: COMPARATOR
Intervention: Non-HIV infected individuals with SAT
Number of subjects: 225
Study 30325779 — intervention group
Group type: COMPARATOR
Intervention: Non-HIV infected individuals with VAT
Number of subjects: 225
Study 30325779 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV group with reduced SAT
Number of subjects: 225
Study 30325779 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV group with increased VAT
Number of subjects: 225
Study 30326301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pan-enteric capsule endoscopy (PCE)
Number of subjects: 46
Study 30326301 — intervention group
Group type: EXPERIMENTAL
Intervention: PCE
Number of subjects: 46
Study 30326324 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30326728 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushed nasal cells
Number of subjects: 0
Study 30326968 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized clinical data and biological samples collection
Number of subjects: 1500
Study 30326968 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological samples (blood, saliva, endoscopic ultrasound-guided fine needle aspiration materials, fine needle biopsy of metastases, and surgically resected tissue)
Number of subjects: 1500
Study 30327354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone Body Infusion
Number of subjects: 0
Study 30327360 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational glucose tolerance
Number of subjects: 0
Study 30327360 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 30327405 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-year risk prediction models for total cardiovascular diseases (CVD)
Number of subjects: 0
Study 30327405 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-year risk prediction models for all-cause mortality
Number of subjects: 0
Study 30327597 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 0
Study 30327597 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropeptide Y
Number of subjects: 0
Study 30327598 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day home-based jigsaw puzzle intervention (≥1 h/day) plus four sessions of cognitive health counseling
Number of subjects: 100
Study 30327598 — intervention group
Group type: COMPARATOR
Intervention: Cognitive health counseling only
Number of subjects: 100
Study 30327612 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intake of energy
Number of subjects: 1140
Study 30327731 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial injection with 40 mg of Methylprednisolone Acetate and 2 ml of Lidocaine
Number of subjects: 20
Study 30328062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) via mid-gut
Number of subjects: 139
Study 30328062 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual preparation of fecal microbiota
Number of subjects: 139
Study 30328062 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic preparation of fecal microbiota
Number of subjects: 139
Study 30328062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota purification methods
Number of subjects: 139
Study 30328062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 139
Study 30328739 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin (KP) levels in the UI group
Number of subjects: 86
Study 30328739 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin (KP) levels in the PCOS group
Number of subjects: 86
Study 30328739 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin (KP) levels in the MFI group
Number of subjects: 86
Study 30328739 — intervention group
Group type: COMPARATOR
Intervention: Comparison of KP levels across groups
Number of subjects: 86
Study 30328739 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic performance of KP in PCOS
Number of subjects: 86
Study 30328739 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential treatment for UI
Number of subjects: 86
Study 30328739 — intervention group
Group type: EXPERIMENTAL
Intervention: KP as a marker for AFC and diagnosis of PCOS
Number of subjects: 86
Study 30328801 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic predictors
Number of subjects: 0
Study 30328801 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30328928 — intervention group
Group type: COMPARATOR
Intervention: Normal lung function group (n=147)
Number of subjects: 205
Study 30328928 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal lung function group (n=58)
Number of subjects: 205
Study 30328967 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 28
Study 30328967 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 28
Study 30328967 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 30333050 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral debriefing
Number of subjects: 24
Study 30333050 — intervention group
Group type: COMPARATOR
Intervention: Oral debriefing assisted by video
Number of subjects: 24
Study 30333052 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness and PAP (Physical Activity on Prescription)
Number of subjects: 90
Study 30333052 — intervention group
Group type: COMPARATOR
Intervention: Only PAP
Number of subjects: 90
Study 30333052 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness only
Number of subjects: 90
Study 30333122 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival staging system incorporating BNP
Number of subjects: 0
Study 30333160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive risk score developed from 4 factors (NIH Stroke Scale score on admission ≥7, among others)
Number of subjects: 404
Study 30333224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerdulatinib (oral administration, dose-escalation, once-daily or twice-daily schedules)
Number of subjects: 43
Study 30333224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerdulatinib (oral administration)
Number of subjects: 43
Study 30333303 — intervention group
Group type: EXPERIMENTAL
Intervention: S4injury score
Number of subjects: 454
Study 30333303 — intervention group
Group type: EXPERIMENTAL
Intervention: S2TCMR score
Number of subjects: 454
Study 30333303 — intervention group
Group type: COMPARATOR
Intervention: Histology diagnoses
Number of subjects: 454
Study 30333794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio-Pulmonary Exercise (CPX) testing in individuals with Type 1 Diabetes (T1D)
Number of subjects: 14
Study 30333794 — intervention group
Group type: COMPARATOR
Intervention: Cardio-Pulmonary Exercise (CPX) testing in healthy individuals (CON)
Number of subjects: 14
Study 30333892 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ-100
Number of subjects: 180
Study 30333892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 30334093 — intervention group
Group type: EXPERIMENTAL
Intervention: Finite element modeling (FE) and computed tomography (CT) measures of bone structure at the knee.
Number of subjects: 101
Study 30334093 — intervention group
Group type: EXPERIMENTAL
Intervention: Finite element modeling (FE) measures of stiffness under axial compression and torsional loading.
Number of subjects: 101
Study 30334093 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-derived measures of bone mineral density (vBMD) and bone mineral content (BMC).
Number of subjects: 101
Study 30334147 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0
Study 30334147 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0
Study 30334192 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve block (PNB)
Number of subjects: 1623
Study 30334192 — intervention group
Group type: COMPARATOR
Intervention: No peripheral nerve block (PNB)
Number of subjects: 1623
Study 30334263 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroTest in NAFLD
Number of subjects: 1079
Study 30334263 — intervention group
Group type: COMPARATOR
Intervention: FibroTest in chronic hepatitis C (CHC)
Number of subjects: 1079
Study 30334263 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic value of FibroTest in NAFLD
Number of subjects: 1079
Study 30334263 — intervention group
Group type: COMPARATOR
Intervention: Prognostic value of FibroTest in CHC
Number of subjects: 1079
Study 30334387 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Axis Deviation (LAD) group
Number of subjects: 292
Study 30334387 — intervention group
Group type: COMPARATOR
Intervention: Normal Axis group
Number of subjects: 292
Study 30334521 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma release assays (IGRAs)
Number of subjects: 10045
Study 30334521 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin skin test (TST)
Number of subjects: 10045
Study 30334521 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tests (TST and IGRAs)
Number of subjects: 10045
Study 30334527 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast volume quartile Q1 (≤100 ml)
Number of subjects: 10961
Study 30334527 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast volume quartile Q2 (101-140 ml)
Number of subjects: 10961
Study 30334527 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast volume quartile Q3 (141-200 ml)
Number of subjects: 10961
Study 30334527 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast volume quartile Q4 (>200 ml)
Number of subjects: 10961
Study 30334909 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel 100 mg/m² (n=84)
Number of subjects: 181
Study 30334909 — intervention group
Group type: EXPERIMENTAL
Intervention: doxorubicin 75 mg/m² (n=97)
Number of subjects: 181
Study 30334942 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH VN intervention (4 core sessions on problem solving, mood management/cognitive restructuring, stress management, and communication, plus up to 2 additional sessions based on caregiver's needs)
Number of subjects: 50
Study 30334942 — intervention group
Group type: COMPARATOR
Intervention: Enhanced control condition (single session providing verbal and written information on dementia)
Number of subjects: 50
Study 30335142 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors of purpura fulminans (PF)
Number of subjects: 37
Study 30335142 — intervention group
Group type: COMPARATOR
Intervention: Survivors of septic shock (unexposed group)
Number of subjects: 37
Study 30335142 — intervention group
Group type: EXPERIMENTAL
Intervention: Amputated patients (n=12/37)
Number of subjects: 37
Study 30335438 — intervention group
Group type: COMPARATOR
Intervention: BPI
Number of subjects: 287
Study 30335438 — intervention group
Group type: COMPARATOR
Intervention: MDD
Number of subjects: 287
Study 30335438 — intervention group
Group type: COMPARATOR
Intervention: BPII
Number of subjects: 287
Study 30335438 — intervention group
Group type: COMPARATOR
Intervention: ANX
Number of subjects: 287
Study 30335480 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant near ACVR1B (activin A receptor type 1B)
Number of subjects: 0
Study 30335559 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI (glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler)
Number of subjects: 138
Study 30335559 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI
Number of subjects: 138
Study 30335570 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care-based surveillance
Number of subjects: 0
Study 30335781 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG pattern recognition (EMG-PR)
Number of subjects: 36
Study 30335781 — intervention group
Group type: COMPARATOR
Intervention: Inertial measurement units (IMU)
Number of subjects: 36
Study 30335787 — intervention group
Group type: EXPERIMENTAL
Intervention: 211At-BC8-B10
Number of subjects: 0
Study 30336349 — intervention group
Group type: COMPARATOR
Intervention: Bipolar Disorder (BD)
Number of subjects: 744
Study 30336349 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD and BD co-morbidity
Number of subjects: 744
Study 30336349 — intervention group
Group type: COMPARATOR
Intervention: Bipolar Disorder (BD) and Healthy Controls (CTRL)
Number of subjects: 744
Study 30336349 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline Personality Disorder (BPD) and ADHD
Number of subjects: 744
Study 30336349 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD and BPD
Number of subjects: 744
Study 30336349 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic childhood experiences
Number of subjects: 744
Study 30336478 — intervention group
Group type: EXPERIMENTAL
Intervention: Beam walking under single task conditions (beam walking only)
Number of subjects: 532
Study 30336478 — intervention group
Group type: EXPERIMENTAL
Intervention: Beam walking under dual task conditions (beam walking while concurrently performing an arithmetic task)
Number of subjects: 532
Study 30336478 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of falling and fall history reported 6 and 12 months after test 1
Number of subjects: 532
Study 30336478 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability of beam walking performance retested 7 to 10 days after test 1
Number of subjects: 532
Study 30336693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential afatinib and osimertinib
Number of subjects: 204
Study 30336704 — intervention group
Group type: EXPERIMENTAL
Intervention: Frustration fMRI paradigm (cued-attention task)
Number of subjects: 195
Study 30336717 — intervention group
Group type: EXPERIMENTAL
Intervention: High adult activity
Number of subjects: 813
Study 30336717 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer weekday sleep
Number of subjects: 813
Study 30336717 — intervention group
Group type: EXPERIMENTAL
Intervention: Family income >$35,000
Number of subjects: 813